In two transgenic C. elegans strains expressing human amyloid-β, 20 µM rapamycin delayed paralysis in the muscle-expressing CL4176 line (log-rank p = 0.0001), improved crawling and swimming, and rescued a chemotaxis deficit in the pan-neuronal CL2355 line (ANOVA p = 0.008). It also extended survival and preserved locomotor healthspan. Notably, rapamycin did not significantly change amyloid-β burden, and chemotaxis in non-transgenic controls was unaffected.
This evidence comes from roundworms, not humans, and it is a preprint that has not yet been peer-reviewed. The most interesting result is the dissociation: benefit without less amyloid. That fits a growing view that mTORC1 inhibition protects through downstream stress-resistance and proteostasis pathways rather than simple plaque clearance, which also helps explain why amyloid-lowering alone has delivered modest clinical returns. Rapamycin's lifespan-extending effects in mice are well established, and some rodent AD models show cognitive benefit, but worm work cannot predict human brain penetration, dosing, or tolerability. Rapamycin's known side effects, including immunosuppression, mouth ulcers, and metabolic changes, matter at human doses. The worms were also exposed to a single concentration, so no dose-response is established. Nothing here supports adults taking rapamycin for dementia prevention; human trials are the missing link. Treat this as confirmatory, incremental preclinical evidence that strengthens the mechanistic rationale for ongoing human rapamycin studies, pending peer review.